Myelin-oligodendrocyte glycoprotein antibody (MOG-Ab)

Interested in submitting an E-Pearl?
Brought to you by the Residents & Fellows Section of Neurology®.

October 23, 2014

Myelin-oligodendrocyte glycoprotein (MOG) is a transmembrane protein located within the outermost layer of the myelin sheath, specific to the central nervous system. A specific Ig domain on the external surface is susceptible to circulating antibodies present within the extracellular space. Such antibodies (MOG-Abs) are potentially pathogenic and have previously been described in childhood demyelinating cases of acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS). More recent research has shown correlations of MOG-Ab reactivity in adult demyelinating diseases, most notably the neuromyelitis optica spectrum disorders (NMOSD). Although NMO is classically associated with specific antibodies to the aquaporin-4 (AQP4) channel, up to 5-40% of NMO patients may be classified as AQP4-seronegative. In patients with a monophasic episode of optic neuritis and transverse myelitis concerning for NMO and are AQP4-seronegative, MOG-Abs have shown positive reactivity and often have a morefavorable response to immunotherapy.


  1. Kitley J et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012; 79: 1273-1277.
  2. Probstel AK et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.  Neurology. 2011; 77: 580-588.  

Submitted by James Addington, MD, Resident Physician, Department of Neurology University of Virginia.

Dr. Addington is a member of the Resident and Fellow Section of Neurology.

For more clinical pearls and other articles of interest to neurology trainees, visit the Neurology Residents & Fellows page.  Listen to this week's Neurology Podcast.


Forgot password?